Quality of Life of the Patients with Melisma

Çoban, Melis

doi:10.4172/2471-9323.1000133

Cited by 3 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies done in India have shown mean DLQI as 9.92 ± 3.01, 16 in Iranian study DLQI as 6.90 ± 4.11, 17 in Singapore mean DLQI value was 4.5 ± 5.07, South Korea DLQI as 6.70 ± 2.3718 and in Turkey mean DLQI value as 6.02 ± 3.84. 14 In two Nepalese studies on melisma, 9,19 the mean DLQI was 6.81 ± 1.34 and 10.9 ± 5.41 respectively. However, previous studies in Pakistan have shown severe impairment in quality of life with DLQI scores of 17.08 ± 5.28 in females as compared to 16.00 ± 0.93 in males.…”

Section: Discussionmentioning

confidence: 90%

“…17 Some other studies have shown a weak, statistically insignificant correlation between MASI and DLQI1. 6,23 Turkish study by Coban et al, 14 has shown DLQI significantly related to educational status (p-value 0.037). In contrast, studies from Latin America have shown people of the lower socio-economic group were affected more by melasma.…”

Section: Discussionmentioning

confidence: 94%

“…The DLQI is a ten-item questionnaire that has high face validity with patients. 14 It assesses six domains potentially hampering a person's quality of life. The first two questions are about symptoms and emotional impact.…”

Section: Methodsmentioning

confidence: 99%

See 2 more Smart Citations

Quality of Life of Melasma Patients in Pakistan

Rahman

Basit

Mohsin

et al. 2022

PAFMJ

View full text Add to dashboard Cite

Objective: To assess the quality of life in Pakistani melasma patients. Study Design: Cross-sectional study. Place and Duration of Study: Department of Dermatology, Combined Military Hospital Lahore, from Oct 2020 to May 2021. Methodology: The study was conducted on 126 adult patients of both genders by non-probability, consecutive sampling technique. Melasma severity was assessed by 'melasma area severity index (MASI) and quality of life impairment by 'dermatology life quality index (DLQI). Results: A total of 126 patients participated in the study, out of which 85.7% were females, and 14.3% were males. Mean MASI score was 12.21 ± 6.87, and mean DLQI score was 8.22 ± 7.46. Male patients had higher MASI scores and statistically signifycant DLQI than female patients (p=0.016). Employed people and those from the higher socio-economic group showed a more significant impairment of their quality of life. Conclusion: There was moderate impairment of quality of life in melasma patients. Healthcare givers need to recognize the effect of melasma on mental health while counselling patients and devising management strategies.

show abstract

Section: Discussionmentioning

confidence: 90%

Section: Discussionmentioning

confidence: 94%

See 1 more Smart Citation

Quality of Life of Melasma Patients in Pakistan

Rahman

Basit

Mohsin

et al. 2022

PAFMJ

View full text Add to dashboard Cite

show abstract

A randomized controlled clinical trial to evaluate safety and efficacy of a Unani formulation in the management of Kalaf (Melasma)

Qaiyyum

Nawab

Kazmi

2021

Journal of Complementary and Integrative Medicine

View full text Add to dashboard Cite

Objectives Kalaf (Melasma) is an acquired facial hypermelanism. It has direct impact on patient’s quality of life and leads to development of various personality disorders. Lack of effective treatment and recurrences have drawn the attention of researcher to find alternative treatment. This study aimed to evaluate safety and efficacy of a topical Unani formulation in the management of melasma. Methods We conducted a prospective randomized controlled clinical study on the participants diagnosed with melasma. The participants (n=72) randomized into test (n=36) and control (n=36) groups. Sixty participants (n=30 in each group) completed the duration of therapy. The participants of the test group were treated with a classical Unani formulation and control group with hydroquinone 4%. The primary end point was change in mean MASI score and secondary end point was improvement in quality of life after eight weeks of treatment. Results The Unani formulation reduced 40.5% mean MASI score (17.31 ± 9.58 to 10.28 ± 5.92) in comparison to 32% reduction in mean MASI score (20.58 ± 9.49 to 13.92 ± 7.38) in the control group after eight weeks of treatment. When comparing with baseline the difference in MASI score was found statistically significant in both groups (p<0.05). On intergroup comparison, the change in MASI score between both groups was not statistically significant (p>0.05). In addition, MQOL and DQLI also improved significantly in both groups. Conclusions This study concluded that the Unani formulation and the control drug were equally effective and safer in the management of melasma.

show abstract